Intellia Therapeutics
NTLA
Market cap $1.06B

11.54 USD

-0.62

5.10%

At close Jul 11, 4:00 PM EDT

After hours

11.55

+0.01

0.09%

1 day

-5.10%

5 days

8.36%

1 month

37.87%

3 months

55.74%

6 months

14.83%

Year to date

-5.56%

1 year

-53.15%

5 years

-46.20%

10 years

-47.78%

About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Employees: 598

Healthcare Biotechnology

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

13% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 45

9% more call options, than puts

Call options by funds: $7.04M | Put options by funds: $6.43M

0% more funds holding

Funds holding: 289 [Q4 2024] → 290 (+1) [Q1 2025]

0.34% more ownership

Funds ownership: 97.45% [Q4 2024] → 97.79% (+0.34%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q4 2024] → 2 (+0) [Q1 2025]

2% less repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 95

38% less capital invested

Capital invested by funds: $1.16B [Q4 2024] → $720M (-$438M) [Q1 2025]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

13%

downside

Avg. target

$34

195%

upside

High target

$68

489%

upside

7 analyst ratings

5 positive

71%

2 neutral

29%

0 negative

0%

HC Wainwright & Co. Mitchell Kapoor	160%upside $30	Buy Reiterated	16 Jun 2025
Canaccord Genuity Whitney Ijem	368%upside $54	Buy Maintained	3 Jun 2025
Wedbush David Nierengarten	13%downside $10	Neutral Reiterated	19 May 2025
Guggenheim Debjit Chattopadhyay	290%upside $45	Buy Maintained	12 May 2025
Citigroup David Lebowitz	13%downside $10	Neutral Maintained	9 May 2025

See Analyst Rankings

Financial journalist opinion

Based on 5 articles about NTLA published over the past 30 days

24/7 Wall Street

Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future

Key Points in This Article: The Magnificent 7 transformed markets through AI and digital ecosystems, turning a once-pejorative label into a celebrated symbol of innovation and growth.

Move Over, Magnificent 7: The Frontier 7 Will Redefine Our Future

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on July 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

NTLA stock surges 29.8% in a month, driven by gene therapy pipeline progress and growing investor attention.

Intellia Gains 29.8% in a Month: How Should You Play the Stock?

Zacks Investment Research

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced three-year follow-up data from the Phase 1 portion of the ongoing Phase 1/2 study in patients with HAE after receiving a single dose of lonvoguran ziclumeran (lonvo-z, also known as NTLA-2002). Results were shared in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, held June 13-16 in Glasgow, United Kingdom.

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on June 1, 2025, it awarded an inducement grant to six new employees under Intellia's 2024 Inducement Plan as a material inducement to employment.

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%

Zacks Investment Research

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Intellia stock tanks after a patient in its phase III study evaluating gene therapy candidate nex-z in ATTR-CM experiences serious liver enzyme elevation.

NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

Intellia Therapeutics Inc NTLA said on Wednesday that a single, recent, asymptomatic patient has had grade 4 (severe) liver transaminase elevations (liver enzymes) based on laboratory tests in its Phase 3 MAGNITUDE study.

Intellia Therapeutics' Rare Heart Disease Candidate Reports Liver Enzyme Spike In Phase 3 Trial, But Stays On Course

Analysts Think These Stocks Could More Than Double in Value

Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more. Investors might remember that many of the biggest rallies take place during these volatile periods, and there may be potential to win big gains for those with at least a moderate tolerance for risk.

Analysts Think These Stocks Could More Than Double in Value

See News Rankings

Charts implemented using Lightweight Charts™